Pulmonary arterial hypertension, or PAH, is a rare disease that is characterized by abnormally high blood pressure in the blood vessels carrying deoxygenated blood from the right side of the heart to the lungs. It is caused by abnormal cell growth in and around these vessels, leading to structural and functional changes known as vascular remodeling. In the U.S., an estimated 30,000 to 50,000 people live with PAH. The five-year survival rate is about 57%.
Although several vasodilators and diuretics have been approved to manage PAH, significant unmet clinical needs persist. Current therapies often involve complex administration methods, including continuous intravenous infusions, which carry risks of infection, require bulky external pumps, and are associated with substantial side effects. While these treatments can alleviate symptoms, they do not halt disease progression.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.